Somatropin long-acting - OPKO Health

Drug Profile

Somatropin long-acting - OPKO Health

Alternative Names: hGH-CTP; Human growth hormone-CTP; MOD-4023; PF-06836922

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Modigene
  • Developer OPKO Health
  • Class Biological proteins; Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 30 Dec 2016 OPKO Health completes a phase III trial in Somatotropin deficiency (in adults) in US, UK, Austria, Greece, Hungary, Netherlands, Poland, Slovakia, and Spain
  • 01 Dec 2016 Phase-III clinical trials in Somatotropin deficiency (In children) in USA (SC)
  • 27 Oct 2015 OPKO Health plans a phase III trial for Growth Hormone deficiency in paediatric patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top